Drugs Made In America Acquisition DMAA Ratios (2024-2026)

NASDAQ DMAA
$10.89 +0.01 (+0.09%)
At close: Oct 1, 2026 · 4:00 PM EDT
Reported Financials

Drugs Made In America Acquisition Quarterly Ratios

Periods 6 quarters
Latest Jun 2026

Drugs Made In America Acquisition ratios data for the quarter ended Jun 2026. These financial ratios cover 6 quarters of results from Dec 2024 through Jun 2026, standardized by Business Quant from the company’s SEC filings.

Ratios Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Jun2026
Efficiency
Assets AverageAssets Avg. 116.68M234.01M236.42M238.78M193.41M
Equity AverageEquity Avg. -3.71M-7.16M-7.24M-7.30M-7.34M
Invested CapitalInvested Cap. 0.42M-7.12M-7.06M
Leverage & Solvency
Debt Ratio 1.200.000.00
Valuation
Price to EarningsP/E 54.9151.17
Enterprise Value 248.40M341.87M344.22M326.22M328.13M
Market Capitalization 248.40M341.87M344.22M326.23M328.15M
Return Ratios
Return on Capital Employed [ROCE]ROCE -1.18%-1.38%
Return on Assets [ROA]ROA 2.49%3.32%

Drugs Made In America Acquisition Ratios API

Pull Drugs Made In America Acquisition's standardized financial statements into your own models, spreadsheets and apps with the Business Quant Financial Statements API. The request below follows the statement, frequency and period selected above. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/statements?ticker=DMAA&statement=Ratios&frequency=Quarter&period=all&api_key=YOUR_API_KEY